Boston – September 22, 2026 -- Viva-Thera has nominated a preclinical candidate targeting the membrane-proximal external region (MPER) of HIV-1 gp41, completing discovery and optimization in seven months through a partnership with AI drug-design firm XtalPi (HKEX: 2228). The biotech, incubated and backed by XtalPi as a strategic shareholder, made its public debut disclosing progress across four HIV modalities: vaccines, long-acting small molecules, gene therapy and cell therapy.

Philadelphia – September 22, 2026 -- Health Union and DTC Perspectives have launched a strategic partnership to stage an invitation-only executive summit focused on redefining commercial models for rare disease and niche oncology marketing.

New York – September 22, 2026 -- PulsePoint has launched DTC Explorer, a self-service workspace that lets pharma marketers build and publish clinically-informed consumer audiences in hours instead of the longer timelines previously required for custom segment creation.

Philadelphia – September 22, 2026 -- IntegriChain will send five senior advisors to three Informa Connect industry conferences this fall, addressing government pricing, 340B compliance, and gross-to-net forecasting for biopharma manufacturers navigating tightening reimbursement rules.

Austin, Texas – September 22, 2026 -- Oracle has been named a Leader in the IDC MarketScape: Worldwide Life Sciences R&D RWD/RWE for Data Platforms, Technology Solutions, and Consulting Services 2026 Vendor Assessment, according to a report published by IDC in August 2026 (Doc #US54122226).

San Diego – September 22, 2026 -- Circular Genomics and Altoida have entered a collaboration pairing blood-based circular RNA (circRNA) biomarkers with AI-powered digital cognitive testing to accelerate Alzheimer's drug development and build a scalable frontline diagnostic pathway.

Holon, Israel – September 22, 2026 -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) will host a virtual key opinion leader event on October 5, 2026 at 8:00 AM ET, presenting new detail on COM701, its anti-PVRIG antibody candidate for relapsed platinum-sensitive ovarian cancer (PSOC).

Boulder, Colorado – September 22, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) disclosed preclinical data showing its lead cardiac drug candidate EDG-7500 improves heart relaxation while preserving systolic function, a mechanism the company says addresses a core driver of hypertrophic cardiomyopathy (HCM) that current therapies do not fully target.

Redmond – September 22, 2026 -- SystImmune Inc. has secured U.S. Food and Drug Administration clearance for its Investigational New Drug application for SI-B037, a bispecific antibody, marking the first time the company has built a regulatory submission entirely on New Approach Methodologies (NAMs) rather than traditional animal toxicology studies.

Uppsala, Sweden – September 22, 2026 -- Beactica Therapeutics AB has initiated IND-enabling studies for BEA-17, a first-in-class oral degrader targeting the epigenetic regulators LSD1 and CoREST, moving the glioblastoma therapy toward first-in-human trials.